ARTICLE | Finance

Hatching Pandion

Why Polaris built its own platform for immunology play Pandion

January 18, 2018 11:54 PM UTC

After scouring academia for novel treatment approaches to autoimmune and inflammatory diseases and coming up empty-handed, Polaris Partners formed Pandion Therapeutics Inc. to develop its own platform from the ground up.

Backed with a $58 million series A round, Pandion is developing bispecific antibodies that restore immune homeostasis at the site of inflammatory and autoimmune disease. The round closed on Jan. 18. ...